475 related articles for article (PubMed ID: 25203320)
1. Vulnerabilities of mutant SWI/SNF complexes in cancer.
Helming KC; Wang X; Roberts CWM
Cancer Cell; 2014 Sep; 26(3):309-317. PubMed ID: 25203320
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights.
Wang X; Haswell JR; Roberts CW
Clin Cancer Res; 2014 Jan; 20(1):21-7. PubMed ID: 24122795
[TBL] [Abstract][Full Text] [Related]
3. Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy.
Wanior M; Krämer A; Knapp S; Joerger AC
Oncogene; 2021 May; 40(21):3637-3654. PubMed ID: 33941852
[TBL] [Abstract][Full Text] [Related]
4. Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers.
Chabanon RM; Morel D; Postel-Vinay S
Semin Cancer Biol; 2020 Apr; 61():180-198. PubMed ID: 31568814
[TBL] [Abstract][Full Text] [Related]
5. The genetic alteration spectrum of the SWI/SNF complex: The oncogenic roles of BRD9 and ACTL6A.
Sima X; He J; Peng J; Xu Y; Zhang F; Deng L
PLoS One; 2019; 14(9):e0222305. PubMed ID: 31504061
[TBL] [Abstract][Full Text] [Related]
6. BAFfling pathologies: Alterations of BAF complexes in cancer.
Arnaud O; Le Loarer F; Tirode F
Cancer Lett; 2018 Apr; 419():266-279. PubMed ID: 29374542
[TBL] [Abstract][Full Text] [Related]
7. Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities.
St Pierre R; Kadoch C
Curr Opin Genet Dev; 2017 Feb; 42():56-67. PubMed ID: 28391084
[TBL] [Abstract][Full Text] [Related]
8. Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities.
Orlando KA; Nguyen V; Raab JR; Walhart T; Weissman BE
Expert Rev Anticancer Ther; 2019 May; 19(5):375-391. PubMed ID: 30986130
[TBL] [Abstract][Full Text] [Related]
9. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
10. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
Kim KH; Kim W; Howard TP; Vazquez F; Tsherniak A; Wu JN; Wang W; Haswell JR; Walensky LD; Hahn WC; Orkin SH; Roberts CW
Nat Med; 2015 Dec; 21(12):1491-6. PubMed ID: 26552009
[TBL] [Abstract][Full Text] [Related]
11. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.
Kadoch C; Hargreaves DC; Hodges C; Elias L; Ho L; Ranish J; Crabtree GR
Nat Genet; 2013 Jun; 45(6):592-601. PubMed ID: 23644491
[TBL] [Abstract][Full Text] [Related]
12. The SWI/SNF complex in cancer - biology, biomarkers and therapy.
Mittal P; Roberts CWM
Nat Rev Clin Oncol; 2020 Jul; 17(7):435-448. PubMed ID: 32303701
[TBL] [Abstract][Full Text] [Related]
13. Synthetic lethal therapy based on targeting the vulnerability of SWI/SNF chromatin remodeling complex-deficient cancers.
Sasaki M; Ogiwara H
Cancer Sci; 2020 Mar; 111(3):774-782. PubMed ID: 31955490
[TBL] [Abstract][Full Text] [Related]
14. SWI/SNF chromatin remodeling and human malignancies.
Masliah-Planchon J; Bièche I; Guinebretière JM; Bourdeaut F; Delattre O
Annu Rev Pathol; 2015; 10():145-71. PubMed ID: 25387058
[TBL] [Abstract][Full Text] [Related]
15. The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer.
Nguyen VT; Tessema M; Weissman BE
Cancer Treat Res; 2023; 190():211-244. PubMed ID: 38113003
[TBL] [Abstract][Full Text] [Related]
16. A rationale to target the SWI/SNF complex for cancer therapy.
Hohmann AF; Vakoc CR
Trends Genet; 2014 Aug; 30(8):356-63. PubMed ID: 24932742
[TBL] [Abstract][Full Text] [Related]
17. Genome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI/SNF Complexes.
Raab JR; Resnick S; Magnuson T
PLoS Genet; 2015 Dec; 11(12):e1005748. PubMed ID: 26716708
[TBL] [Abstract][Full Text] [Related]
18. SWI/SNF Complex Mutations in Gynecologic Cancers: Molecular Mechanisms and Models.
Wang Y; Hoang L; Ji JX; Huntsman DG
Annu Rev Pathol; 2020 Jan; 15():467-492. PubMed ID: 31977292
[TBL] [Abstract][Full Text] [Related]
19. The spectrum of SWI/SNF mutations, ubiquitous in human cancers.
Shain AH; Pollack JR
PLoS One; 2013; 8(1):e55119. PubMed ID: 23355908
[TBL] [Abstract][Full Text] [Related]
20. Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF.
Radko-Juettner S; Yue H; Myers JA; Carter RD; Robertson AN; Mittal P; Zhu Z; Hansen BS; Donovan KA; Hunkeler M; Rosikiewicz W; Wu Z; McReynolds MG; Roy Burman SS; Schmoker AM; Mageed N; Brown SA; Mobley RJ; Partridge JF; Stewart EA; Pruett-Miller SM; Nabet B; Peng J; Gray NS; Fischer ES; Roberts CWM
Nature; 2024 Apr; 628(8007):442-449. PubMed ID: 38538798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
